The development of early vaccines began in the early18th century, when people were vaccinated with vaccinia vaccine for human immunity test. During this period, it has experienced hundreds of years of development. At present, vaccines can prevent more than 20 diseases in the world, and infectious diseases such as diphtheria, pertussis, tetanus, measles, polio and tuberculosis have been basically controlled. 2 1 century, the medical model will shift from treating diseases to preventing diseases, and the vaccine industry will usher in more rapid development.
The number of vaccine patent applications in the United States ranks first in the world.
Vaccine research and development has the characteristics of large capital investment, long time period and high risk of failure, so the accumulation of technology patents can reflect the current competitiveness. From the global distribution of vaccine-related patents, the United States, China and Europe have the largest number of patent applications, among which the United States ranks first with 4 1.79%, while China and the European Patent Office account for 22.80% and1.25% respectively.
Note: Patent data were obtained by searching for keywords such as "vaccine", "immune vaccine" and "DNA vaccine" on the platform of Wisdom Bud, and the data ended on March 22, 2022.
Merck HPV vaccine has become the best-selling commodity.
At present, the role of vaccines is still mainly to prevent diseases, so the vaccine with the largest audience in the world to prevent diseases is usually in greater demand. According to the sales revenue of major vaccine products in 20021world, among the major vaccine products in 20021world, the HPV vaccine of Merck, the Prevnar series of Pfizer, and the influenza vaccine of Sanofi all performed well, reaching US$ 5.673 billion, US$ 5.272 billion and US$ 365,438+0./kloc-0 respectively.
Note: British pound and euro are converted according to the average exchange rate of 202 1, 1 euro = 1. 1837 USD, 1 pound = 1.3764 USD.
Children's vaccines have a high market share.
In recent years, influenza vaccine, cervical cancer vaccine, pneumonia vaccine and other fields have developed rapidly, and the global adult vaccine market has been growing. It is predicted that the global adult vaccine market share will be about 40% in 20021year. The main varieties of children's vaccines are pneumonia vaccine, combined vaccine, varicella vaccine, hepatitis vaccine and measles vaccine. Among them, pneumonia vaccine occupies the main market share, and the global market share of Children's Vaccine 202/KLOC-0 is about 60%.
The global market has exceeded $60 billion.
With the increase of global vaccination demand, the support of the government and international institutions, and the development of new vaccines, the demand for vaccines in the global market has greatly increased. In terms of sales revenue, the global vaccine market has grown from $42.9 billion in 20 16 to $57.3 billion in 2020, with a compound annual growth rate of 7.5%. According to preliminary estimation, it will reach $60.2 billion in 202 1 year.
—— The above data refer to the analysis report of Prospective Industry Research Institute "Development Prospect and Investment Strategic Planning of China Vaccine Industry".